Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants

JAMA Netw Open. 2021 Oct 1;4(10):e2129742. doi: 10.1001/jamanetworkopen.2021.29742.

Authors

Grace O'Brien¹, Kurt D Christensen^{2

3}, Haley K Sullivan^{2

4}, Natasha K Stout^{2

3}, Lisa Diller^{3

5}, Jennifer M Yeh^{1

3}, Ann Chen Wu^{1

3}

Affiliations

¹ Boston Children's Hospital, Boston, Massachusetts.
² Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts.
⁴ Harvard University, Cambridge, Massachusetts.
⁵ Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

This economic evaluation examines the costs and benefits of cascade testing of siblings of newborns with cancer susceptibility gene variants.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Cost-Benefit Analysis
Female
Genetic Predisposition to Disease
Genetic Testing / economics*
Genetic Testing / standards
Genetic Testing / statistics & numerical data
Humans
Infant, Newborn
Male
Mutation / genetics
Neoplasms / diagnosis
Neoplasms / genetics*

Grants and funding